Submit your comments on this article |
Government |
Trump sparks global outrage after cornering the world's supply of Gilead's remdesivir |
2020-07-02 |
[Daily Mail, where America gets its news]
|
Posted by:Skidmark |
#10 The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors. |
Posted by: Shating Turkeyneck1016 2020-07-02 13:54 |
#9 fuck your outrage |
Posted by: Chris 2020-07-02 13:45 |
#8 World is outraged that the USA has the most cases and the most deaths. |
Posted by: Bobby 2020-07-02 10:04 |
#7 Unclear how much US paid but Gilead prices it at $3,200 per treatment course Since Trump's involved in the negotiations, I know it's not $3,200 a pop; ST1016's prices look like the right range. the potentially life-saving drug Thank you, Johnny fucking One-Note... |
Posted by: Raj 2020-07-02 07:23 |
#6 Makes me wonder if corporatists/fascists (from an economic stand point) such as Mussolini, et al., would love such an arrangement. Gilead. Ha, gee, who would have guessed? I don't trust the pharmaceutical-industrial complex as far as I can throw it. |
Posted by: Clem 2020-07-02 06:53 |
#5 ISTR this deal has been public record for months. |
Posted by: Rob Crawford 2020-07-02 06:11 |
#4 Mind you, good reelection-wise step: "To me, Americans come first". |
Posted by: g(r)omgoru 2020-07-02 05:50 |
#3 the potentially life-saving drug |
Posted by: g(r)omgoru 2020-07-02 04:36 |
#2 The US will not be at the mercy of the makers of these lifesaving drugs to allow exuberant costs at the outset of their employment. Surely, you would be compensated as you had more customers in the long run, or not? |
Posted by: newc 2020-07-02 03:45 |
#1 Indian licensees free to price Remdesivir: Gilead US drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies — Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India, but none of these firms has received approval from the drug controller. most of the four companies are ready with their products and are awaiting nod from the regulator to manufacture and start selling the drug in the country. A private physician in Mumbai said distributors of Hetero Pharma, one of the licensees in India, are quoting ₹7,000 per 100 mg vial for the generic version of Remdesivir — even ahead of its formal approval. At this price, a five-day full course, which was approved by the Indian authorities on Monday, would cost ₹35,000-42,000 ($463-556). Hetero declined to comment and ET could not independently verify these figures. |
Posted by: Shating Turkeyneck1016 2020-07-02 03:19 |